Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03235050 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects With Type 2 Diabetes
A Phase 2 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 834
- Enrollment target
NCT03235050: Completed Phase 2 study, sponsored by AstraZeneca.
NCT03235050 is a Phase 2 study that has completed, run by AstraZeneca. The registered enrollment target is 834 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (527% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03235050, a Phase 2 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 834 participants
- Enrollment target
Study Summary
This study is designed to evaluate the dose range for MEDI0382 with respect to blood glucose control and weight loss effects, as well as to further explore the safety profile of MEDI0382
Primary Outcome
To assess the effect of 100, 200, 300 μg of cotadutide on HbA1c versus placebo
Interventions
- DRUG Placebo
- DRUG Liraglutide
- DRUG MEDI0382 low dose
- DRUG MEDI0382 mid dose
- DRUG MEDI0382 high dose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 834 participants |
| Start Date | 2017-08-02 |
| Est. Completion | 2019-06-14 |
| Phase | Phase 2 |
What the finished NCT03235050 record still lists
NCT03235050 is an interventional study that assigns participants to a tested intervention. The registered 834 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (527% higher).
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT03235050 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03235050 about?
NCT03235050 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects With Type 2 Diabetes". This study is designed to evaluate the dose range for MEDI0382 with respect to blood glucose control and weight loss effects, as well as to further explore the safety profile of MEDI0382
What is the current status of trial NCT03235050?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 834 participants. The study started on 2017-08-02. Estimated completion is 2019-06-14.
What interventions are being tested in trial NCT03235050?
The interventions under investigation include: Placebo (DRUG), Liraglutide (DRUG), MEDI0382 low dose (DRUG), MEDI0382 mid dose (DRUG), MEDI0382 high dose (DRUG).
Who is sponsoring clinical trial NCT03235050?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03235050's enrollment target sits among peer trials
834 36th of 2000 higher than 1,965 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03670524 · 835 participants · NA
Health, Environment and Action in Louisville (HEAL) Green Heart Louisville Project
- NCT02118467 · 836 participants · Phase 4
Vasoactive Drugs in Intensive Care Unit
- NCT06910553 · 832 participants
IBD Pregnancy Registry
- NCT07089706 · 832 participants · Phase 4
A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Variant-containing Formulations
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI